Literature DB >> 17333641

When and how to fix a 'hole in the heart': approach to ASD and PFO.

Richard A Krasuski1.   

Abstract

Abnormalities in the atrial septum range in severity from patent foramen ovale (PFO), a residual cardiac structure found in approximately 25% of the general population, to uncommon, complex lesions associated with significant shunt flow and heart enlargement. While correcting some of these abnormalities is beneficial, most other defects warrant correction only under very specific circumstances.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17333641     DOI: 10.3949/ccjm.74.2.137

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  4 in total

1.  Should patent foramen ovale be closed in patients with recent cryptogenic stroke or presumptive platypnea-orthodeoxia syndrome?

Authors:  Giovanni Saeed
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Patent foramen ovale: anatomical complexity and long-tunnel morphology related issues.

Authors:  Giampiero Vizzari; Fausto Pizzino; Dianne Zwicke; A Jamil Tajik; Scipione Carerj; Gianluca Di Bella; Antonio Micari; Bijoy K Khandheria; Concetta Zito
Journal:  Am J Cardiovasc Dis       Date:  2021-06-15

Review 3.  The brain's heart - therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease.

Authors:  Mingming Ning; Eng H Lo; Pei-Chen Ning; Su-Yu Xu; David McMullin; Zareh Demirjian; Ignacio Inglessis; G William Dec; Igor Palacios; Ferdinando S Buonanno
Journal:  Pharmacol Ther       Date:  2013-03-23       Impact factor: 12.310

Review 4.  Percutaneous treatment of patients with heart diseases: selection, guidance and follow-up. A review.

Authors:  Carla Contaldi; Maria-Angela Losi; Antonio Rapacciuolo; Maria Prastaro; Raffaella Lombardi; Valentina Parisi; Lucia S Parrella; Carlo Di Nardo; Alessandra Giamundo; Roberto Puglia; Giovanni Esposito; Federico Piscione; Sandro Betocchi
Journal:  Cardiovasc Ultrasound       Date:  2012-03-27       Impact factor: 2.062

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.